In the SUSTAIN 1-7 series of clinical trials which investigated the effectiveness of once weekly semaglutide injections (Ozempic) for the treatment of diabetic and obese patients, semaglutide (Ozempic) consistently demonstrated significant reductions in HbA1c levels compared to placebo and other usual diabetes medications (metformin, sitagliptin, dulaglutide)
Based on these studies, the FDA approved Wegovy injections for chronic weight management ONLY in adults with a BMI over 30 or over 27 with at least one weight-related condition (high blood pressure, type 2 diabetes, or high cholesterol)
Noom goes one step further with its SmartDose program, a highly personalized, "low and slow" titration method that effectively doubles the number of dose steps and includes more frequent check-ins than the standard protocol
Many customers report noticeable reductions in between-meal hunger, smoother digestion, and steadier daily energy levels within the first month of use